Cite
HARVARD Citation
Oaknin, A. et al. (n.d.). 39/#452 Immune-related endpoints in patients with advanced or recurrent endometrial cancer treated with dostarlimab in the garnet study. International journal of gynecological cancer. p. A43. [Online].